Skip to main content
. Author manuscript; available in PMC: 2024 Dec 4.
Published in final edited form as: Science. 2024 Jul 4;385(6704):46–53. doi: 10.1126/science.adk8946

Figure 4: Antibodies evolved for high potency also exhibit improved affinity.

Figure 4:

(A) LY-CoV1404 antibody variants show a Spearman correlation of 0.45 between apparent affinity fold-change and potency fold-change. Improved affinity is observed to be necessary but not sufficient for improved neutralization activity. Four variants exhibit improved affinity but do not enhance neutralization. All variants with improved neutralization also display improved affinity. The top LY-CoV1404 design with a 25-fold improvement in neutralization has a 9.5-fold improvement in affinity to BQ.1.1 RBD, as measured using BLI. (C) SA58 antibodies evolved for improved potency against BQ.1.1 also exhibit improved affinity against VOC XBB.1.5, up to 37-fold. (B, D) Representative traces of BLI binding assays for LY-CoV1404 and SA58 variants with improved affinity.